文献速递艾滋病与性传播感染

初治HIV患者双药与三药治疗失败风险的系统综述与Meta分析

Risk of failure in dual therapy versus triple therapy in naïve HIV patients: a systematic review and meta-analysis.
PubMed 文献 · Clin Microbiol Infect · 2020-10-05

48周时双药与三药在治疗失败、病毒学失败及因不良反应停药方面均无显著差异,但CD4<200的患者双药治疗失败风险升高,且96周时双药治疗耐药突变选择风险更高。

要点

  • 初治HIV患者双药与三药治疗在48周疗效及安全性上总体无显著差异。
  • CD4<200的患者双药治疗失败风险显著升高,RR 2.09(95%CI 1.05-4.17)。
  • 96周时双药治疗耐药突变选择风险更高,RR 1.94(95%CI 1.06-3.53)。

核心结论

  • 双药治疗与三药治疗在初治HIV患者中总体疗效相当,但CD4<200的患者双药治疗失败风险升高,且96周时耐药突变选择风险更高。

主要发现

  • 48周时,10项研究的治疗失败RR为1.20(95%CI 0.91-1.59,I2=49.2%)。
  • 48周时,8项研究的病毒学失败RR为1.54(95%CI 0.84-2.86,I2=54%)。
  • 48周时,8项研究因不良反应停药的RR为0.76(95%CI 0.43-1.33,I2=17.7%)。
  • CD4<200的患者中,2项不含马拉维若的研究治疗失败RR为2.09(95%CI 1.05-4.17,I2=0.0%)。
  • 96周时,除耐药发生风险RR为1.94(95%CI 1.06-3.53,I2=6.2%)外,其余无差异。

临床怎么用

  • 初治HIV患者可考虑双药治疗,但CD4<200的患者应谨慎选择双药方案,并加强耐药监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Several attempts have been made to test different drug-sparing strategies to reduce the drug-burden and drug-related toxicities. The objective of this meta-analysis was to evaluate the relative risk (RR) of failure of dual therapies compared to triple therapies in HIV-naïve patients. METHODS: We searched MEDLINE, Google Scholar and the Cochrane Library. The following criteria were used: present data from original articles comparing the two treatment regimens; published from January 2007 up to January, 2020. No language or study design restriction was applied. Subjects were HIV-positive naïve patients treated with dual or triple antiretroviral therapy (ART). A systematic review and meta-analysis was performed. Treatment failure (TF) was the primary outcome evaluated; heterogeneity was assessed using the Q statistic and I2. RESULTS: Fourteen studies were included, allowing a meta-analysis on 5205 patients. The meta-analysis performed on studies that presented data at 48 weeks showed that the RR of TF (RR > 1 favouring triple therapy) in 10 studies was 1.20 (95% confidence interval (CI): 0.91-1.59, I2: 49.2%); the RR of virological failure (VF) in eight studies was 1.54 (95% CI: 0.84-2.86, I2: 54%); the RR of adverse drug reaction leading to discontinuation of the regimen at 48 weeks in eight studies was 0.76 (95% CI: 0.43-1.33, I2: 17.7%). In patients with less than 200 CD4+, the RR of TF in two studies without maraviroc was 2.09 (95% CI: 1.05-4.17, I2: 0.0%). Regarding the studies at 96 weeks there was no difference except in rate of development of resistance, RR 1.94 (95% CI: 1.06-3.53, I2: 6.2%). CONCLUSION: Dual therapies are as effective as those with three drugs, showing no difference according to the different dual therapies, except in patients with less than 200 CD4; however, they are associated with a higher selection of resistance-associated mutations at 96 weeks of therapy.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Pisaturo M, Onorato L, Russo A, et al. Risk of failure in dual therapy versus triple therapy in naïve HIV patients: a systematic review and meta-analysis. Clin Microbiol Infect. 2020. PMID: 33031949. doi:10.1016/j.cmi.2020.09.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。